Public limited company · Wavre · incorporated on 14/04/2005 · 1,9 ETP
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 3,8 M € | +50.5% | 2,5 M € | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||||||||||||||
| Gross margin | 1,5 M € | +227.6% | 456,6 k € | -18.0% | 557,0 k € | +11.2% | 501,0 k € | +19.5% | 419,2 k € | +5.2% | 398,5 k € | +81.4% | 219,8 k € | -32.7% | 326,7 k € | +2.4% | 319,1 k € | +22.1% | 261,2 k € | +93.1% | 135,3 k € | -5.6% | 143,3 k € | -2.3% | 146,6 k € | +101.7% | 72,7 k € | -0.9% | 73,4 k € | +226.4% | -58,0 k € | -199.2% | 58,5 k € | -5.3% | 61,7 k € | +1246.1% | 4,6 k € | |
| EBITDA | 1,4 M € | +323.8% | 331,2 k € | -20.6% | 417,3 k € | +3.2% | 404,2 k € | +31.4% | 307,6 k € | +1.9% | 302,0 k € | +343.0% | 68,2 k € | -67.6% | 210,6 k € | -6.9% | 226,1 k € | +26.7% | 178,4 k € | +1026.2% | 15,8 k € | -34.1% | 24,1 k € | -75.7% | 99,2 k € | +1063.0% | 8,5 k € | -79.5% | 41,7 k € | +178.2% | -53,3 k € | -175.8% | 70,3 k € | +23.4% | 57,0 k € | +350.5% | -22,8 k € | |
| Operating profit | 1,4 M € | +355.1% | 300,6 k € | -20.7% | 379,0 k € | +17.2% | 323,5 k € | +31.3% | 246,4 k € | -5.8% | 261,6 k € | +1346.4% | 18,1 k € | -90.5% | 190,9 k € | -6.7% | 204,7 k € | +26.0% | 162,5 k € | +2794.1% | 5,6 k € | -36.3% | 8,8 k € | -89.7% | 85,7 k € | +3169.2% | 2,6 k € | -91.9% | 32,3 k € | +141.2% | -78,4 k € | -248.7% | 52,7 k € | +1473.8% | 3,3 k € | +105.2% | -64,7 k € | |
| Profit/loss | 932,9 k € | +382.7% | 193,3 k € | -27.1% | 265,0 k € | +32.3% | 200,3 k € | -16.3% | 239,2 k € | -5.5% | 253,2 k € | +1563.6% | 15,2 k € | -91.7% | 182,3 k € | -6.6% | 195,1 k € | +34.7% | 144,8 k € | +5004.6% | 2,8 k € | -59.4% | 7,0 k € | -91.3% | 80,7 k € | +1211.8% | 6,1 k € | -82.8% | 35,7 k € | +150.0% | -71,4 k € | -223.4% | 57,9 k € | +414.9% | 11,2 k € | +119.9% | -56,5 k € | |
| Equity | 2,6 M € | +54.9% | 1,7 M € | +12.8% | 1,5 M € | +21.4% | 1,2 M € | +19.3% | 1,0 M € | +29.9% | 800,5 k € | +23.7% | 647,4 k € | -11.6% | 732,2 k € | +33.2% | 549,9 k € | +55.0% | 354,8 k € | +69.0% | 210,0 k € | +1.4% | 207,1 k € | +3.5% | 200,1 k € | +67.5% | 119,5 k € | +5.4% | 113,3 k € | +42.4% | 79,6 k € | -48.7% | 155,2 k € | +49.9% | 103,6 k € | +6.6% | 97,2 k € | |
| Total assets | 4,8 M € | +55.9% | 3,1 M € | +15.6% | 2,7 M € | +31.8% | 2,0 M € | +61.7% | 1,3 M € | +13.6% | 1,1 M € | +16.7% | 945,1 k € | -2.9% | 972,9 k € | +26.1% | 771,7 k € | +52.1% | 507,5 k € | +55.3% | 326,7 k € | +0.5% | 325,0 k € | -4.0% | 338,6 k € | +59.8% | 211,9 k € | -5.1% | 223,2 k € | +20.5% | 185,1 k € | -11.0% | 208,0 k € | -0.4% | 208,8 k € | -5.9% | 221,9 k € | |
| Cash | 531,2 k € | -44.0% | 947,8 k € | +264.9% | 259,7 k € | -29.2% | 366,8 k € | -10.5% | 409,8 k € | +137.6% | 172,5 k € | +96.7% | 87,7 k € | -22.2% | 112,7 k € | +16.5% | 96,7 k € | +45.5% | 66,5 k € | +68.1% | 39,5 k € | +17.5% | 33,6 k € | -73.8% | 128,4 k € | +2007.6% | 6,1 k € | -37.3% | 9,7 k € | +10.0% | 8,8 k € | -79.4% | 42,9 k € | +593.8% | 6,2 k € | -84.9% | 41,0 k € | |
| Debts | 2,0 M € | +66.5% | 1,2 M € | +11.5% | 1,1 M € | +42.3% | 762,4 k € | +336.5% | 174,6 k € | -4.8% | 183,5 k € | -1.4% | 186,1 k € | +45.7% | 127,7 k € | +24.9% | 102,2 k € | +235.8% | 30,4 k € | -28.5% | 42,6 k € | -13.5% | 49,2 k € | -47.4% | 93,4 k € | +56.2% | 59,8 k € | -32.8% | 89,1 k € | +37.2% | 64,9 k € | +127.7% | 28,5 k € | -38.7% | 46,5 k € | -40.3% | 77,8 k € | |
| Staff | 1 | 1,9 | 2,5 | 2,6 | 1,6 | 2,6 | 2,8 | 2,8 | 2,3 | 1,3 | 1,7 | 2,3 | 1,5 | 0,9 | 1 | — | — | — | — | |||||||||||||||||||
Public limited company profitable and well capitalised. Cash position declining (-44.0%).
Acceptable counterparty for a moderate engagement. Require 2 fiscal years of detailed accounts before any significant exposure. The abridged model hides revenue.
LUCIMED is a Public limited company incorporated in 2005. Its main activity is: Wholesale of pharmaceutical goods. Its registered office is in Wavre. It employs on average 1,9 ETP workers (FTE).
Key indicators
7-day free trial, no credit card required.
7-day free trial, no credit card required.
7-day free trial, no credit card required.
Source: Belgian Official Gazette